Improvement in Key PsA Core Domains With Guselkumab Treatment in an Enriched Population of ACR20 Non-responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies

McGonagle, D., Haaland, D., Helliwell, P. orcid.org/0000-0002-4155-9105 et al. (6 more authors) (2023) Improvement in Key PsA Core Domains With Guselkumab Treatment in an Enriched Population of ACR20 Non-responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies. In: ACR Convergence 2022, 10-14 Nov 2022, Philadelphia, PA.